Dicerna Pharma (DRNA) Misses Q3 EPS by 23c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. LLY
4. META
5. FICO
6. TSLA
7. SPCX
8. MSFT
9. AZN
10. FLG

Go back to Dicerna Pharma (DRNA) Misses Q3 EPS by 23c

Dicerna Reports Third Quarter 2017 Financial and Operating Results and Provides Corporate Update

November 2, 2017 4:05 PM EDT

Management to Host Conference Call Today at 4:30 p.m. ET

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the third quarter ended September 30, 2017.

We are extremely pleased with the progress we made during the third quarter, and the fourth quarter is off to a great start, highlighted by the achievement of two key milestones for the Company, said Douglas M. Fambrough, Ph.D., president and chief executive officer of Dicerna.... More